Trial Condition(s):
Macular degeneration
Regorafenib eye drops: Investigation of efficacy and safety in neovascular age related macular degeneration (DREAM)
Bayer Identifier:
15984
ClinicalTrials.gov Identifier:
EudraCT Number:
EU CT Number:
Not Available
Trial Purpose
Part A (Phase IIa):
Primary objectives:
The study part A is designed to investigate whether the use of regorafenib eye drops can help patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4 weeks and 12 weeks after inclusion into this study.
Secondary objectives:
The study will also evaluate the safety and tolerability of the regorafenib eye drops.
Part B (Phase IIb):
Primary objectives:
The study part B is designed to investigate:
- how often the regorafenib eye drops need to be given per day
- whether the use of regorafenib eye drops can help patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4 weeks and 12 weeks after inclusion into this study.
Secondary objectives:
The study will also evaluate how the different dosings of regorafenib eye drops affect patients vision, the safety and the tolerability.
Inclusion Criteria
- Able to read (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member) and able to understand the informed consent form (ICF) - Men and women ≥ 50 years of age - Active primary subfoveal CNV (Choroidal neovascularization) lesions secondary to AMD (Age-related macular degeneration), including juxtafoveal lesions that affect the fovea as evidenced by FA (Fluorescein angiography) in the study eye and reviewed by the central reading center - The area of CNV must occupy at least 50% of total lesion in the study eye, as determined by FA review at the central reading center - Evidence of intraretinal and/or subretinal fluid on OCT (Optical coherence tomography) - Early Treatment Diabetic Retinopathy Study BCVA of 73 to 25 letters (20/40 to 20/320 Snellen equivalent) in the study eye - Willing, committed, and able to return for all clinic visits and complete all study related procedures - Women of childbearing potential and men must agree to use adequate contraception when sexually active. This applies since signing of the ICF until one month after the EOS (end of study) visit. The definition of adequate contraception will be based on the judgment of the investigator.
Exclusion Criteria
- Concurrent disease in the study eye, other than AMD (e.g., corneal diseases and dystrophies, conjunctival diseases, eye lid abnormalities, or any other diseases of the cornea and macula, or optic nerve abnormality) that could compromise visual acuity, likely require medical or surgical intervention during the study period, would limit the potential to gain or lose vision during study treatment, or could otherwise confound interpretation of the results - Total lesion size (including neovascularization, scar, blood) > 12 disc areas (30.5 mm2) as assessed by FA - Only one functional eye, even if that eye is otherwise eligible for the study - Prior ocular or systemic treatment or surgery for neovascular AMD in the study eye except dietary supplements or vitamins - Prior treatment with any systemic anti-VEGF (Vascular endothelial growth factor) agent - Use of systemic or ocular treatment with an investigational drug within 12 weeks prior to start of study treatment - Any other condition that would require frequent chronic co-administration of other topical eye medications that would interfere with study drug administration (e.g. contact lens) - Symptoms or conditions consistent with contraindications listed in the current local label for ranibizumab - Participation in an investigational study within 30 days prior to start of study treatment that involved treatment with any drug (excluding vitamins and minerals) or device - Lactating women and women of child-bearing potential with either a positive pregnancy test result or no pregnancy test at screening are excluded. Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential.
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Praha 4, Czech Republic, 140 00 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Bern, Switzerland, 3010 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Wien, Austria, 1090 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Wien, Austria, 1130 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Hamburg, Germany, 20251 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Bonn, Germany, 53105 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Münster, Germany, 48145 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site München, Germany, 81675 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Berlin, Germany, 12203 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Petah Tikva, Israel, 4941492 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Rehovot, Israel, 7610001 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Tel Aviv, Israel, 6423906 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Jerusalem, Israel, 9112001 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Haifa, Israel, 3109601 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Haifa, Israel, 3436212 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kfar Saba, Israel, 4428164 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Zerifin, Israel, 6093000 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Beer Sheva, Israel, 8410101 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sevilla, Spain, 41013 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Valencia, Spain, 46015 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site L'Hospitalet de Llobregat, Spain, 08907 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sevilla, Spain, 41071 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site San Cugat del Vallès, Spain, 08190 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Albacete, Spain, 02006 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Valladolid, Spain, 47012 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Barcelona, Spain, 08035 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Budapest, Hungary, 1133 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Budapest, Hungary, 1106 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Budapest, Hungary, 1082 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Debrecen, Hungary, 4032 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Paris, France, 75557 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site BOREDAUX, France, 33076 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Lyon, France, 69003 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Praha 2, Czech Republic, 128 08 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Praha 7, Czech Republic, 170 00 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Hradec Kralove, Czech Republic, 500 05 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Dresden, Germany, 01307 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Dresden, Germany, 01067 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Valencia, Spain, 46014 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Vitacura, Chile, 7650710 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Santiago, Chile, 8380456 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Bogota, Colombia, 0 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Trencin, Slovakia, 91171 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Bratislava, Slovakia, 85107 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Zilina, Slovakia, 01207 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Ruzomberok, Slovakia, 03426 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Pecs, Hungary, 7621 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Miami, United States, 33143 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Louisville, United States, 40207 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Austin, United States, 78705 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Asheville, United States, 28803 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Winter Haven, United States, 33880 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Greenville, United States, 29605 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Wichita, United States, 67226 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Eunice, United States, 70535 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Campbell, United States, 95008 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Laguna Hills, United States, 92653 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sarasota, United States, 34239 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Beverly Hills, United States, 90211 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Leawood, United States, 66211 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Grand Rapids, United States, 49525 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Decatur, United States, 30030 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Milano, Italy, 20157 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Ancona, Italy, 60126 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Padova, Italy, 35128 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Roma, Italy, 00133 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Milano, Italy, 20122 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Roma, Italy, 00198 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Barakaldo, Spain, 48903 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Osorno, Chile, 5311138 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Metropolitana, Chile, 7510168 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Zürich, Switzerland, 8063 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Seoul, South Korea, 137-701 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Seongnam-si, South Korea, 463-707 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Seoul, South Korea, 135-710 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Seoul, South Korea, 03080 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Stuart, United States, 34994 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Costa Mesa, United States, 92626 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Westmead, Australia, 2145 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Parramatta, Australia, 2150 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Strathfield, Australia, 2135 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sydney, Australia, 2000 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kowloon, Hong Kong, China | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Hong Kong, Hong Kong, China | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Plantation, United States, 33324 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Tucson, United States, 85704 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Temple, United States, 76508 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Fort Myers, United States, 33912 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Santa Ana, United States, 92705 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Golden, United States, 80401 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Zilina, Slovakia, 01008 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site London, Canada, N6A 4V2 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Calgary, Canada, T2H 0C8 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site New Albany, United States, 47150 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Arcadia, United States, 91007 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Teaneck, United States, 07666 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Mountain View, United States, 94040 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Milano, Italy, 20132 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Firenze, Italy, 50134 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Udine, Italy, 33100 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Halifax, Canada, B3H 2Y9 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Edmonton, Canada, T5H 0X5 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Vancouver, Canada, V5Z 3N9 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Seoul, South Korea, 05505 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Lausanne, Switzerland, 1004 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Nedlands, Australia, 6009 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Incheon, South Korea, 405-760 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Bologna, Italy, 40138 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sassari, Italy, 07100 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Tübingen, Germany, 72076 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Mainz, Germany, 55131 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Köln, Germany, 50937 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Leipzig, Germany, 04103 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site München, Germany, 81377 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Busan, South Korea, 49241 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Mississauga, Canada, L4W 1W9 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Montreal, Canada, H4P 2S4 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Ramat Gan, Israel, 5262000 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Afula, Israel, 1834111 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Rapid City, United States, 57701 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Houston, United States, 77030 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site West Mifflin, United States, 15122 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site McAllen, United States, 78503 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Charlottesville, United States, 22908 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site San Antonio, United States, 78240 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site The Woodlands, United States, 77384 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Boston, United States, 02114 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Florissant, United States, 63031 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Montreal, Canada, H1T 2M4 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Nagasaki, Japan, 852-8511 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Nara, Japan, 630-8305 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Osaka, Japan, 533-0024 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sapporo, Japan, 060-8604 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kumamoto, Japan, 860-0027 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Yamato, Japan, 242-0001 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Itabashi-ku, Japan, 173-0015 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Ota-ku, Japan, 143-0013 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Chofu, Japan, 182-0024 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Taito-ku, Japan, 111-0051 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Osaka, Japan, 530-0001 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Yokohama, Japan, 222-0011 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Himeji, Japan, 671-1227 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Iga, Japan, 518-0842 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sapporo, Japan, 004-0041 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Inba-gun, Japan, 285-0922 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Miyako-gun, Japan, 800-0344 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Fukuoka, Japan, 812-0011 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Boynton Beach, United States, 33426 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sherbrooke, Canada, J1J 2B8 | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
A combined Phase IIa / IIb study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naïve subjects with neovascular age related macular degeneration
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Treatment
Allocation:
Randomized
Blinding:
Double Blind
Assignment:
Parallel Assignment
Trial Arms:
8
Primary Outcome
- Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Study Week 4 for Study Part AParticipants will be assessed at each clinic visit for best corrected visual acuity using the early treatment diabetic retinopathy study chart. Visual function of the study eye and the fellow eye was assessed using the ETDRS. The participant’s ETDRS testing score was recorded in the appropriate eCRF page at each study visit. For participants that dropped out or received rescue treatment the last observation before drop-out or administration of rescue treatment was carried forward. A higher score represents better functioning.Timeframe: Baseline, Week 4
- Change From Baseline in BCVA as Measured by ETDRS Letter Score at Study Week 12 for Study Part AParticipants were assessed at each clinic visit for best corrected visual acuity using the early treatment diabetic retinopathy study chart. Visual function of the study eye and the fellow eye was assessed using the ETDRS protocol. ETDRS testing score was recorded in the appropriate eCRF page at each study visit. For participants that dropped out or received rescue treatment the last observation before drop-out or administration of rescue treatment was carried forward. A higher score represents better functioning.Timeframe: Baseline, Week 12
Secondary Outcome
- Percentage of Participants With Individual Changes in BCVA of greater than equal to (>=) 0 Letters of Vision From Study Week 4 to Week 12 for Study Part AParticipants were assessed at each clinic visit for BCVA using the early treatment diabetic retinopathy study chart. For participants that dropped out or received rescue treatment the last observation before drop-out or administration of rescue treatment was carried forward.Timeframe: Week 4, Week 12
- Percentage of Participants With a Loss in BCVA of >= 10 Letters From Baseline to Study Week 12 for Study Part AParticipants were assessed at each clinic visit for BCVA using the early treatment diabetic retinopathy study chart. For participants that dropped out or received rescue treatment the last observation before drop-out or administration of rescue treatment was carried forward.Timeframe: Baseline, Week 12
Additional Information
Copyright © Bayer
Powered by
